Oxford AI in Drug Discovery and Medicine Programme
Developed by the Nuffield Department of Medicine, this six-week online programme is your definitive guide to integrating AI tools into the drug R&D pipeline to accelerate life-saving discoveries. No prior coding experience required.
6 weeks entirely online
 5-7 hours per week
Weekly modules, flexible learning
Multiple payment options
On completion of this programme,
you’ll walk away with:
Real-world
research insights
See how world-leading research teams are currently using AI to advance the discovery of new, life-saving medicines.
AI-augmented R&D methodologiesÂ
Learn how to identify a target and formulate a therapeutic design approach that incorporates AI technologies, with key insights from programme speaker Professor Emma Mead.
Familiarity with top industry tools
Become familiar with AI databases and software solutions like Target Safety and MedChemica through live demonstrations in instructor-led workshops.
An AI roadmap for your organisation
Develop a target validation case and a patient subgroup analysis as part of a capstone AI roadmap proposal based on your organisational context.Â
This program is designed for:
Scientifically literate professionals who want to learn how to adopt, utilise or oversee AI tools in their work. This includes:
Scientists and biomedical researchers – Biologists and chemists working in academia and industry who want to keep pace with how AI is reshaping research in the fieldÂ
R&D professionals working in biotech and pharma – Professionals working directly in the drug development pipeline who want to use AI tools to accelerate discoveryÂ
Clinician researchers – MDs, PharmDs and clinical development professionals working at the discovery-to-clinic interface
Programme curriculum
Module 1
Module 2
Module 3
Module 4
Module 5
Your Programme Director
Alex Bullock
Professor of Structural and Chemical Biology, University of OxfordÂ
Alex Bullock is Professor of Structural and Chemical Biology at the Centre for Medicines Discovery at the University of Oxford. His work has defined a novel cancer mechanism of E3 ligase neofunction and identified a drug candidate for fibrodysplasia ossificans progressiva that is currently in Phase II clinical trials.Â
Prior to this, he spent over 15 years at the Structural Genomics Consortium, an international public-private partnership producing structures, assays and inhibitors for novel drug targets – particularly protein kinases and Cullin-RING E3 ligases. He undertook doctoral training at the University of Cambridge with Sir Alan Fersht before holding Wellcome fellowship positions with Sir Peter Ratcliffe on the VHL-HIF pathways (University of Oxford) and in the US with David Barker on Rosetta-based protein design (University of Washington, Seattle).
What is GetSmarter?
GetSmarter delivers online education from world-leading universities and institutions to transform the lives of thousands of students across the globe. GetSmarter’s online certificate courses are designed to advance your career and fit in with your busy lifestyle. Each course is expert-led, fully supported and community-based, helping you build career-critical skills. GetSmarter is owned by 2U.
An online education that sets you apart
This online programme from the University of Oxford is delivered in collaboration with GetSmarter, an online education provider. Join a growing community of global professionals and benefit from the opportunity to:
1
Attend a learning experience that balances the rigour of an Oxford education with the flexibility of online study, including live workshops led by expert instructors and opportunities to connect with the global Oxford network.Â
2
Enjoy a personalised, people-mediated online learning experience designed to support you at every step.
3
Experience a flexible but structured approach to online education as you plan your learning around your life to meet weekly milestones.
Want to know more?
Enter your information to access the programme prospectus and learn more about this course from GetSmarter.